サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1789868

デュピクセントの市場規模、シェア、動向分析レポート：適応症別、流通チャネル別、地域別、セグメント予測、2025年～2033年

Dupixent Market Size, Share & Trends Analysis Report By Indication (Atopic Dermatitis, Asthma, Chronic Rhinosinusitis With Nasal Polyps, Chronic Obstructive Pulmonary Disease ), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2033

出版日
ページ情報
英文 150 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.66円
デュピクセントの市場規模、シェア、動向分析レポート：適応症別、流通チャネル別、地域別、セグメント予測、2025年～2033年
出版日: 2025年07月03日
発行: Grand View Research
ページ情報: 英文 150 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

デュピクセント市場のサマリー

デュピクセントの世界市場規模は2024年に141億5,000万米ドルと推計され、2033年には275億8,000万米ドルに達し、2025年から2033年までのCAGRは7.70%で成長すると予測されています。デュピクセント業界は、従来の治療法から生物製剤への移行を反映しています。

アトピー性皮膚炎、喘息、鼻ポリープを伴う慢性鼻副鼻腔炎を含む2型炎症性疾患の世界の有病率の増加と、水疱性類天疱瘡や好酸球性食道炎などの新たな適応症に対する最近の規制当局の承認が、この成長を牽引しています。市場成長の原動力となっているのは、2型炎症性疾患に対する治療ニーズです。サノフィとリジェネロンが開発したデュピクセントは、臨床試験で有効性と安全性を実証しており、アトピー性皮膚炎や喘息などの疾患において、副腎皮質ステロイドなどの従来の選択肢を凌駕しています。2024年にはアトピー性皮膚炎患者が2億人以上、喘息患者が3億人以上と報告されており、このシフトは世界の有病率の増加に支えられています。

デュピクセント市場拡大の主な要因は研究開発であり、新たな治療領域における臨床試験に支えられています。慢性自然じんま疹を対象としたLIBERTY-CSU CUPIDやアレルギー性真菌性鼻副鼻腔炎を対象とした臨床試験などの進行中の試験は、新たな患者層への薬剤の普及を目指しています。好酸球性食道炎を対象とした小児用臨床試験および水疱性類天疱瘡の承認取得（2024年1月）により、患者適格性が向上し、2033年までの長期的な収益創出の強化が期待されます。実際のエビデンスに裏打ちされたこれらの取り組みにより、デュピクセントは炎症性疾患および希少免疫学的適応症におけるポジショニングを高めています。

サノフィとリジェネロンの世界な提携は、規制当局による承認の迅速化を促進し、市場アクセス基盤を強化します。2025年6月に米国FDAがCOPDと水疱性類天疱瘡を承認したことは戦略的なマイルストーンとなり、デュピクセントの承認適応症は鼻ポリープを伴う慢性鼻副鼻腔炎と結節性痒疹を含む9適応症に拡大した。これにより、デュピクセントはインターロイキン阻害剤クラス別での地位が強化され、北米、欧州、アジア太平洋地域での世界展開が、協調した規制・商業化戦略によって推進されています。

米国や日本などの主要市場では2033年まで特許が保護されているため、中期的にはバイオシミラー医薬品の競合リスクは軽減されます。さらに、製造の複雑さや特殊な施設が新規参入の抑止力となっています。市場拡大のチャンスは、特にラテンアメリカや中東・アフリカなどの未開拓地域に残されています。ブラジルやサウジアラビアなどの国々は、ヘルスケア改革と生物製剤需要の増加に支えられ、大きな患者数を有しています。現地に根ざした価格戦略や販売パートナーシップは、地域アクセスを促進すると期待されます。

欧州における希少疾病用医薬品の独占販売権などの規制上の優遇措置は、強力な開発パイプラインと相まって、持続的な成長を支えています。しかし、欧州とアジア太平洋地域におけるバイオシミラー医薬品の参入や価格設定の制約など、2033年以降の市場力学は、収益性を維持するための適応的な償還戦略と患者アクセスプログラムの必要性を浮き彫りにしています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 デュピクセント市場の変数、動向、および範囲

  • 市場系統の見通し
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • ビジネス環境分析
    • 業界分析- ポーターのファイブフォース分析
    • PESTLE分析
    • パイプライン分析
    • 特許満了分析
    • 価格分析

第4章 デュピクセント市場：適応症別のビジネス分析

  • 適応症別市場シェア分析、2024年および2033年
  • 適応症別セグメントダッシュボード
  • 市場規模、予測、動向分析（適応症別、2021～2033年）
  • アトピー性皮膚炎（AD）
  • 喘息
  • 鼻ポリープを伴う慢性副鼻腔炎（CRSwNP）
  • 慢性閉塞性肺疾患（COPD）
  • その他

第5章 デュピクセント市場：流通チャネル別のビジネス分析

  • 流通チャネル別市場シェア分析、2024年および2033年
  • 流通チャネル別セグメントダッシュボード
  • 市場規模、予測、動向分析（流通チャネル別、2021～2033年）
  • 病院薬局
  • 小売薬局
  • その他

第6章 デュピクセント市場：地域別の推定・動向分析

  • 地域別市場シェア分析、2024年および2033年
  • 地域別セグメントダッシュボード
  • 市場規模と予測動向分析（地域別、2021～2033年）
  • 北米
    • 国別、2021年～2033年
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • デンマーク
    • スウェーデン
    • ノルウェー
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • オーストラリア
    • 韓国
    • タイ
  • ラテンアメリカ
    • ブラジル
    • アルゼンチン
  • 中東およびアフリカ
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第7章 競合情勢

  • 参加者概要
  • 企業の市況分析
  • 企業分類
  • 戦略マッピング
  • 企業プロファイル/上場企業
    • Sanofi
    • Regeneron
図表

List of Tables

  • Table 1. List of secondary sources
  • Table 2. List of abbreviations
  • Table 3. Global Dupixent market, by region, 2021 - 2033 (USD Million)
  • Table 4. Global Dupixent market, by indication, 2021 - 2033 (USD Million)
  • Table 5. Global Dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 6. North America Dupixent market, by country, 2021 - 2033 (USD Million)
  • Table 7. North America Dupixent market, by indication, 2021 - 2033 (USD Million)
  • Table 8. North America Dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 9. U.S. Dupixent market, by indication, 2021 - 2033 (USD Million)
  • Table 10. U.S. Dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 11. Canada Dupixent market, by indication, 2021 - 2033 (USD Million)
  • Table 12. Canada Dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 13. Mexico Dupixent market, by indication, 2021 - 2033 (USD Million)
  • Table 14. Mexico Dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 15. Europe Dupixent market, by country, 2021 - 2033 (USD Million)
  • Table 16. Europe Dupixent market, by indication, 2021 - 2033 (USD Million)
  • Table 17. Europe Dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 18. UK Dupixent market, by indication, 2021 - 2033 (USD Million)
  • Table 19. UK Dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 20. Germany Dupixent market, by indication, 2021 - 2033 (USD Million)
  • Table 21. Germany Dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 22. France Dupixent market, by indication, 2021 - 2033 (USD Million)
  • Table 23. France Dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 24. Italy Dupixent market, by indication, 2021 - 2033 (USD Million)
  • Table 25. Italy Dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 26. Spain Dupixent market, by indication, 2021 - 2033 (USD Million)
  • Table 27. Spain Dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 28. Norway Dupixent market, by indication, 2021 - 2033 (USD Million)
  • Table 29. Norway Dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 30. Denmark Dupixent market, by indication, 2021 - 2033 (USD Million)
  • Table 31. Denmark Dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 32. Sweden Dupixent market, by indication, 2021 - 2033 (USD Million)
  • Table 33. Sweden Dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 34. Asia Pacific Dupixent market, by country, 2021 - 2033 (USD Million)
  • Table 35. Asia Pacific Dupixent market, by indication, 2021 - 2033 (USD Million)
  • Table 36. Asia Pacific Dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 37. Japan Dupixent market, by indication, 2021 - 2033 (USD Million)
  • Table 38. Japan Dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 39. China Dupixent market, by indication, 2021 - 2033 (USD Million)
  • Table 40. China Dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 41. India Dupixent market, by indication, 2021 - 2033 (USD Million)
  • Table 42. India Dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 43. Australia Dupixent market, by indication, 2021 - 2033 (USD Million)
  • Table 44. Australia Dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 45. South Korea Dupixent market, by indication, 2021 - 2033 (USD Million)
  • Table 46. South Korea Dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 47. Thailand Dupixent market, by indication, 2021 - 2033 (USD Million)
  • Table 48. Thailand Dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 49. Latin America Dupixent market, by country, 2021 - 2033 (USD Million)
  • Table 50. Latin America Dupixent market, by indication, 2021 - 2033 (USD Million)
  • Table 51. Latin America Dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 52. Brazil Dupixent market, by indication, 2021 - 2033 (USD Million)
  • Table 53. Brazil Dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 54. Argentina Dupixent market, by indication, 2021 - 2033 (USD Million)
  • Table 55. Argentina Dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 56. Middle East & Africa Dupixent market, by country, 2021 - 2033 (USD Million)
  • Table 57. Middle East & Africa Dupixent market, by indication, 2021 - 2033 (USD Million)
  • Table 58. Middle East & Africa Dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 59. South Africa Dupixent market, by indication, 2021 - 2033 (USD Million)
  • Table 60. South Africa Dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 61. Saudi Arabia Dupixent market, by indication, 2021 - 2033 (USD Million)
  • Table 62. Saudi Arabia Dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 63. UAE Dupixent market, by indication, 2021 - 2033 (USD Million)
  • Table 64. UAE Dupixent market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 65. Kuwait Dupixent market, by indication, 2021 - 2033 (USD Million)
  • Table 66. Kuwait Dupixent market, by distribution channel, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Dupixent market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Therapeutic approach and application outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Dupixent market dynamics
  • Fig. 12 Dupixent market: Porter's five forces analysis
  • Fig. 13 Dupixent market: PESTLE analysis
  • Fig. 14 Product market, 2021 - 2033 (USD Million)
  • Fig. 15 Atopic Dermatitis (AD) market, 2021 - 2033 (USD Million)
  • Fig. 16 Asthma market, 2021 - 2033 (USD Million)
  • Fig. 17 Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) market, 2021 - 2033 (USD Million)
  • Fig. 18 Chronic Obstructive Pulmonary Disease (COPD) market, 2021 - 2033 (USD Million)
  • Fig. 19 Others market, 2021 - 2033 (USD Million)
  • Fig. 20 Distribution Channel market, 2021 - 2033 (USD Million)
  • Fig. 21 Hospital Pharmacies market, 2021 - 2033 (USD Million)
  • Fig. 22 Retail Pharmacies market, 2021 - 2033 (USD Million)
  • Fig. 23 Others market, 2021 - 2033 (USD Million)
  • Fig. 24 Dupixent market revenue, by region
  • Fig. 25 Regional marketplace: Key takeaways
  • Fig. 26 North America Dupixent market, 2021 - 2033 (USD Million)
  • Fig. 27 U.S. country dynamics
  • Fig. 28 U.S. Dupixent market, 2021 - 2033 (USD Million)
  • Fig. 29 Canada country dynamics
  • Fig. 30 Canada Dupixent market, 2021 - 2033 (USD Million)
  • Fig. 31 Mexico country dynamics
  • Fig. 32 Mexico Dupixent market, 2021 - 2033 (USD Million)
  • Fig. 33 Europe Dupixent market, 2021 - 2033 (USD Million)
  • Fig. 34 UK country dynamics
  • Fig. 35 UK Dupixent market, 2021 - 2033 (USD Million)
  • Fig. 36 Germany country dynamics
  • Fig. 37 Germany Dupixent market, 2021 - 2033 (USD Million)
  • Fig. 38 France country dynamics
  • Fig. 39 France Dupixent market, 2021 - 2033 (USD Million)
  • Fig. 40 Italy country dynamics
  • Fig. 41 Italy Dupixent market, 2021 - 2033 (USD Million)
  • Fig. 42 Spain country dynamics
  • Fig. 43 Spain Dupixent market, 2021 - 2033 (USD Million)
  • Fig. 44 Norway country dynamics
  • Fig. 45 Norway Dupixent market, 2021 - 2033 (USD Million)
  • Fig. 46 Sweden country dynamics
  • Fig. 47 Sweden Dupixent market, 2021 - 2033 (USD Million)
  • Fig. 48 Denmark country dynamics
  • Fig. 49 Denmark Dupixent market, 2021 - 2033 (USD Million)
  • Fig. 50 Asia Pacific Dupixent market, 2021 - 2033 (USD Million)
  • Fig. 51 Japan country dynamics
  • Fig. 52 Japan Dupixent market, 2021 - 2033 (USD Million)
  • Fig. 53 China country dynamics
  • Fig. 54 China Dupixent market, 2021 - 2033 (USD Million)
  • Fig. 55 India country dynamics
  • Fig. 56 India Dupixent market, 2021 - 2033 (USD Million)
  • Fig. 57 Australia country dynamics
  • Fig. 58 Australia Dupixent market, 2021 - 2033 (USD Million)
  • Fig. 59 South Korea country dynamics
  • Fig. 60 South Korea Dupixent market, 2021 - 2033 (USD Million)
  • Fig. 61 Thailand country dynamics
  • Fig. 62 Thailand Dupixent market, 2021 - 2033 (USD Million)
  • Fig. 63 Latin America Dupixent market, 2021 - 2033 (USD Million)
  • Fig. 64 Brazil country dynamics
  • Fig. 65 Brazil Dupixent market, 2021 - 2033 (USD Million)
  • Fig. 66 Argentina country dynamics
  • Fig. 67 Argentina Dupixent market, 2021 - 2033 (USD Million)
  • Fig. 68 MEA Dupixent market, 2021 - 2033 (USD Million)
  • Fig. 69 South Africa country dynamics
  • Fig. 70 South Africa Dupixent market, 2021 - 2033 (USD Million)
  • Fig. 71 Saudi Arabia country dynamics
  • Fig. 72 Saudi Arabia Dupixent market, 2021 - 2033 (USD Million)
  • Fig. 73 UAE country dynamics
  • Fig. 74 UAE Dupixent market, 2021 - 2033 (USD Million)
  • Fig. 75 Kuwait country dynamics
  • Fig. 76 Kuwait Dupixent market, 2021 - 2033 (USD Million)
  • Fig. 77 Company categorization
  • Fig. 78 Company market position analysis
  • Fig. 79 Strategic framework
目次
Product Code: GVR-4-68040-657-9

Dupixent Market Summary

The global dupixent market size was estimated at USD 14.15 billion in 2024, and is projected to reach USD 27.58 billion by 2033, growing at a CAGR of 7.70% from 2025 to 2033. The Dupixent industry reflects a transition from traditional therapies to biologics.

Anchored by its innovative interleukin-4 and interleukin-13 inhibition mechanism, this growth is driven by the increasing global prevalence of Type 2 inflammatory diseases, including atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps, along with recent regulatory approvals for new indications such as bullous pemphigoid and eosinophilic esophagitis. The market growth is driven by the need for treatments addressing Type 2 inflammatory diseases. Dupixent, developed by Sanofi and Regeneron, demonstrates efficacy and safety in clinical trials, surpassing conventional options like corticosteroids for conditions including atopic dermatitis and asthma. This shift is supported by increasing global prevalence, with over 200 million atopic dermatitis patients and 300 million asthma cases reported in 2024.

Research and development efforts are a key driver of the Dupixent market's expansion, supported by clinical trials across new therapeutic areas. Ongoing studies such as LIBERTY-CSU CUPID for chronic spontaneous urticaria and trials in allergic fungal rhinosinusitis aim to broaden the drug's reach to new patient populations. Pediatric trials for eosinophilic esophagitis and approved use in bullous pemphigoid (January 2024) are expected to enhance patient eligibility and strengthen long-term revenue generation through 2033. These initiatives, supported by real-world evidence, are increasing Dupixent's positioning across inflammatory and rare immunologic indications.

Sanofi and Regeneron's global collaboration facilitates accelerated regulatory approvals and strengthens market access infrastructure. U.S. FDA approvals in June 2025 for COPD and bullous pemphigoid mark strategic milestones, expanding Dupixent's approved indications to nine, including chronic rhinosinusitis with nasal polyps and prurigo nodularis. This has reinforced the drug's standing in the interleukin inhibitor class, with global rollout in North America, Europe, and Asia Pacific driven by a coordinated regulatory and commercialization strategy.

Patent protection in major markets such as the U.S. and Japan until 2033 reduces biosimilar competition risk in the medium term. Additionally, manufacturing complexity and specialized facilities act as deterrents for new entrants. Market expansion opportunities remain in underpenetrated regions, particularly Latin America and the Middle East & Africa. Countries such as Brazil and Saudi Arabia present significant patient pools, supported by healthcare reforms and increasing biologics demand. Localized pricing strategies and distribution partnerships are expected to drive regional access.

Regulatory incentives such as orphan drug exclusivity in Europe, combined with a strong development pipeline, support sustained growth. However, post-2033 market dynamics, including biosimilar entry and pricing constraints in Europe and Asia Pacific, highlight the need for adaptive reimbursement strategies and patient access programs to maintain profitability.

Global Dupixent Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global Dupixent market report based on indication, distribution channel, and region:

  • Indication Outlook (Revenue, USD Million, 2021 - 2033)
  • Atopic Dermatitis (AD)
  • Asthma
  • Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Others
  • Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Indication
    • 1.2.2. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Dupixent Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. Dupixent Market: Indication Business Analysis

  • 4.1. Indication Market Share, 2024 & 2033
  • 4.2. Indication Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Indication, 2021 to 2033 (USD Million)
  • 4.4. Atopic Dermatitis (AD)
    • 4.4.1. Atopic Dermatitis (AD) Market, 2021 - 2033 (USD Million)
  • 4.5. Asthma
    • 4.5.1. Asthma Market, 2021 - 2033 (USD Million)
  • 4.6. Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
    • 4.6.1. Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, 2021 - 2033 (USD Million)
  • 4.7. Chronic Obstructive Pulmonary Disease (COPD)
    • 4.7.1. Chronic Obstructive Pulmonary Disease (COPD) Market, 2021 - 2033 (USD Million)
  • 4.8. Others
    • 4.8.1. Others Market, 2021 - 2033 (USD Million)

Chapter 5. Dupixent Market: Distribution Channel Business Analysis

  • 5.1. Distribution Channel Market Share, 2024 & 2033
  • 5.2. Distribution Channel Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Million)
  • 5.4. Hospital Pharmacies
    • 5.4.1. Hospital Pharmacies Market, 2021 - 2033 (USD Million)
  • 5.5. Retail Pharmacies
    • 5.5.1. Retail Pharmacies Market, 2021 - 2033 (USD Million)
  • 5.6. Others
    • 5.6.1. Others Market, 2021 - 2033 (USD Million)

Chapter 6. Dupixent Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2024 & 2033
  • 6.2. Regional Market Dashboard
  • 6.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 6.4. North America
    • 6.4.1. North America Dupixent Market Estimates And Forecasts, By Country, 2021 - 2033 (USD Million)
    • 6.4.2. U.S.
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Target Disease Prevalence
      • 6.4.2.3. Regulatory Framework
      • 6.4.2.4. Reimbursement Framework
      • 6.4.2.5. U.S. Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.3. Canada
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Target Disease Prevalence
      • 6.4.3.3. Regulatory Framework
      • 6.4.3.4. Reimbursement Framework
      • 6.4.3.5. U.S. Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.4.4. Mexico
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Target Disease Prevalence
      • 6.4.4.3. Regulatory Framework
      • 6.4.4.4. Reimbursement Framework
      • 6.4.4.5. Mexico Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. Europe
    • 6.5.1. Europe Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.2. UK
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Target Disease Prevalence
      • 6.5.2.3. Regulatory Framework
      • 6.5.2.4. Reimbursement Framework
      • 6.5.2.5. Uk Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.3. Germany
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Target Disease Prevalence
      • 6.5.3.3. Regulatory Framework
      • 6.5.3.4. Reimbursement Framework
      • 6.5.3.5. Germany Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.4. France
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Target Disease Prevalence
      • 6.5.4.3. Regulatory Framework
      • 6.5.4.4. Reimbursement Framework
      • 6.5.4.5. France Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.5. Italy
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Target Disease Prevalence
      • 6.5.5.3. Regulatory Framework
      • 6.5.5.4. Reimbursement Framework
      • 6.5.5.5. Italy Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.6. Spain
      • 6.5.6.1. Key Country Dynamics
      • 6.5.6.2. Target Disease Prevalence
      • 6.5.6.3. Regulatory Framework
      • 6.5.6.4. Reimbursement Framework
      • 6.5.6.5. Spain Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.7. Denmark
      • 6.5.7.1. Key Country Dynamics
      • 6.5.7.2. Target Disease Prevalence
      • 6.5.7.3. Regulatory Framework
      • 6.5.7.4. Reimbursement Framework
      • 6.5.7.5. Denmark Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.8. Sweden
      • 6.5.8.1. Key Country Dynamics
      • 6.5.8.2. Target Disease Prevalence
      • 6.5.8.3. Regulatory Framework
      • 6.5.8.4. Reimbursement Framework
      • 6.5.8.5. Sweden Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.5.9. Norway
      • 6.5.9.1. Key Country Dynamics
      • 6.5.9.2. Target Disease Prevalence
      • 6.5.9.3. Regulatory Framework
      • 6.5.9.4. Reimbursement Framework
      • 6.5.9.5. Norway Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Asia Pacific Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.2. Japan
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Target Disease Prevalence
      • 6.6.2.3. Regulatory Framework
      • 6.6.2.4. Reimbursement Framework
      • 6.6.2.5. Japan Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.3. China
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Target Disease Prevalence
      • 6.6.3.3. Regulatory Framework
      • 6.6.3.4. Reimbursement Framework
      • 6.6.3.5. China Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.4. India
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Target Disease Prevalence
      • 6.6.4.3. Regulatory Framework
      • 6.6.4.4. Reimbursement Framework
      • 6.6.4.5. India Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.5. Australia
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Target Disease Prevalence
      • 6.6.5.3. Regulatory Framework
      • 6.6.5.4. Reimbursement Framework
      • 6.6.5.5. Australia Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.6. South Korea
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Target Disease Prevalence
      • 6.6.6.3. Regulatory Framework
      • 6.6.6.4. Reimbursement Framework
      • 6.6.6.5. South Korea Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.6.7. Thailand
      • 6.6.7.1. Key Country Dynamics
      • 6.6.7.2. Target Disease Prevalence
      • 6.6.7.3. Regulatory Framework
      • 6.6.7.4. Reimbursement Framework
      • 6.6.7.5. Thailand Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Latin America Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.2. Brazil
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Target Disease Prevalence
      • 6.7.2.3. Regulatory Framework
      • 6.7.2.4. Reimbursement Framework
      • 6.7.2.5. Japan Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Target Disease Prevalence
      • 6.7.3.3. Regulatory Framework
      • 6.7.3.4. Reimbursement Framework
      • 6.7.3.5. China Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8. Middle East and Africa
    • 6.8.1. Middle East and Africa Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.2. South Africa
      • 6.8.2.1. Key Country Dynamics
      • 6.8.2.2. Target Disease Prevalence
      • 6.8.2.3. Regulatory Framework
      • 6.8.2.4. Reimbursement Framework
      • 6.8.2.5. South Africa Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.3. Saudi Arabia
      • 6.8.3.1. Key Country Dynamics
      • 6.8.3.2. Target Disease Prevalence
      • 6.8.3.3. Regulatory Framework
      • 6.8.3.4. Reimbursement Framework
      • 6.8.3.5. Saudi Arabia Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.4. UAE
      • 6.8.4.1. Key Country Dynamics
      • 6.8.4.2. Target Disease Prevalence
      • 6.8.4.3. Regulatory Framework
      • 6.8.4.4. Reimbursement Framework
      • 6.8.4.5. UAE Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 6.8.5. Kuwait
      • 6.8.5.1. Key Country Dynamics
      • 6.8.5.2. Target Disease Prevalence
      • 6.8.5.3. Regulatory Framework
      • 6.8.5.4. Reimbursement Framework
      • 6.8.5.5. Kuwait Dupixent Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. Sanofi
      • 7.5.1.1. Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Product Benchmarking
      • 7.5.1.4. Strategic Initiatives
    • 7.5.2. Regeneron
      • 7.5.2.1. Overview
      • 7.5.2.2. Financial Performance
      • 7.5.2.3. Product Benchmarking
      • 7.5.2.4. Strategic Initiatives